IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.58 Consensus PT from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $53.58.

IDYA has been the topic of a number of recent research reports. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Stephens reiterated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th.

IDEAYA Biosciences Stock Performance

IDYA stock traded down $0.01 during trading on Friday, hitting $18.82. 66,598 shares of the company traded hands, compared to its average volume of 947,944. The company has a 50-day moving average of $18.07 and a 200-day moving average of $23.61. The firm has a market capitalization of $1.65 billion, a PE ratio of -5.70 and a beta of 0.51. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analysts' expectations of $7.00 million. Sell-side analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current year.

Institutional Trading of IDEAYA Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its position in shares of IDEAYA Biosciences by 2.6% during the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of IDEAYA Biosciences by 13.5% in the fourth quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after buying an additional 695,263 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after acquiring an additional 282,936 shares in the last quarter. Deerfield Management Company L.P. Series C grew its holdings in shares of IDEAYA Biosciences by 5.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock valued at $70,315,000 after purchasing an additional 142,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in IDEAYA Biosciences by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after purchasing an additional 43,226 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.